The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer.
The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer.
复制标题
DOI：
10.1007/s10552-010-9713-4
复制
发表时间：
2011-03
期刊：
影响因子：
--
通讯作者：
Smith JA Jr
中科院分区：
文献类型：
--
作者：
Fowke JH;Motley SS;Barocas DA;Cookson MS;Concepcion R;Byerly S;Smith JA Jr
先前的研究报告他汀类药物可能会降低晚期前列腺癌的风险。本研究调查了他汀类药物的使用与PSA或DRE检测、血液PSA水平、前列腺体积和下尿路症状严重程度之间的关系。我们还描述了他汀类药物使用与前列腺癌和高级别前列腺上皮内瘤变（PIN）之间的关联，在控制与他汀类药物使用相关的前列腺癌筛查指标之前和之后。纳什维尔男性健康研究采用多中心、快速招募方案，从2,148名40岁或40岁以上的男性中收集临床、生物学、行为和身体测量数据，这些男性计划进行诊断性前列腺活检。药物使用和其他数据通过研究调查，临床访谈和图表审查来确定。大约37%的参与者正在服用他汀类药物。在控制了年龄、种族、BMI、WHR、阿司匹林使用和其他合并症后，他汀类药物的使用与PSA水平降低12%和前列腺体积减小8%显著相关。辛伐他汀与前列腺体积的相关性更强，而阿托伐他汀与PSA相关。他汀类药物的使用与未确诊癌症的男性PSA检测频率增加无关。他汀类药物的使用与直肠指检的频率或结果、下尿路症状的严重程度、高级别（Gleason >6）前列腺癌（OR=0.95（0.73，1.24））、低级别（Gleason = 6）前列腺癌（OR=1.11（0.86，1.42））或PIN（OR=0.82，（0.57，1.17））无关。对既往PSA检测次数、PSA水平和前列腺体积进行额外控制并没有改变这些结果。这些结果表明，选择性转诊与他汀类药物使用相关的活检是进一步了解他汀类药物预防前列腺癌潜力的一个重要因素。
Prior studies report statins may reduce the risk of advanced prostate cancer. This study investigates the association between statin use and the likelihood of having a PSA or DRE test, blood PSA levels, prostate volume, and the severity of lower urinary tract symptoms. We also describe the association between statin use and prostate cancer and high-grade prostatic intraepithelial neoplasia (PIN) before and after controlling for prostate cancer screening indices associated with statin use. The Nashville Men's Health Study used a multicenter, rapid recruitment protocol to collect clinical, biological, behavioral and body measurement data from 2,148 men 40 years or older scheduled for diagnostic prostate biopsy. Medication use and other data were ascertained by research survey, clinical interview, and chart review. Approximately 37% of participants were taking a statin. Statin use was significantly associated with a 12% lower PSA levels and 8% smaller prostate volume after controlling for age, race, BMI, WHR, aspirin use, other comorbidity. Simvastatin was more strongly associated with prostate volume, while atorvastatin was associated with PSA. Statin use was marginally associated with increasing PSA test frequency among men with undiagnosed cancer. Statin use was not associated with the frequency or results of digital rectal exams, lower urinary tract symptom severity, high-grade (Gleason >6) prostate cancer (OR=0.95 (0.73, 1.24)), low-grade (Gleason = 6) prostate cancer (OR=1.11 (0.86, 1.42)) or PIN (OR=0.82, (0.57, 1.17)). Additional control for the number of prior PSA tests, PSA levels, and prostate volume did not alter these results. These results suggest selective referral for biopsy associated with statin use is an essential element to address in further understanding the potential for statins to prevent prostate cancer.
登录
查看更多内容
影响因子：
10.3
作者：
Platz, Elizabeth A.;Leitzmann, Michael F.;Giovannucci, Edward
通讯作者：
Giovannucci, Edward
DOI：
10.1016/j.urolonc.2004.10.005
发表时间：
2004-11-01
影响因子：
2.7
作者：
Moyad, MA
通讯作者：
Moyad, MA
影响因子：
23.4
作者：
Mills, Ian W.;Crossland, Anna;Ramonas, Henrikas
通讯作者：
Ramonas, Henrikas
影响因子：
4.5
作者：
Parsons, J. Kellogg;Bergstrom, Jaclyn;Barrett-Connor, Elizabeth
通讯作者：
Barrett-Connor, Elizabeth
影响因子：
3.8
作者：
Banez, Lionel L.;Klink, Joseph C.;Freedland, Stephen J.
通讯作者：
Freedland, Stephen J.